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Background: This study was designed to evaluate primarily the safety and 
also the efficacy of moxifloxacin (MXF) in children with complicated intra-
abdominal infections (cIAIs).
Methods: In this multicenter, randomized, double-blind, controlled study, 
451 pediatric patients aged 3 months to 17 years with cIAIs were treated 
with intravenous/oral MXF (N = 301) or comparator (COMP, intravenous 
ertapenem followed by oral amoxicillin/clavulanate; N = 150) for 5 to 14 
days. Doses of MXF were selected based on the results of a Phase 1 study in 
pediatric patients (NCT01049022). The primary endpoint was safety, with 
particular focus on cardiac and musculoskeletal safety; clinical and bacte-
riologic efficacy at test of cure was also investigated.
Results: The proportion of patients with adverse events (AEs) was com-
parable between the 2 treatment arms (MXF: 58.1% and COMP: 54.7%). 
The incidence of drug-related AEs was higher in the MXF arm than in 
the COMP arm (14.3% and 6.7%, respectively). No cases of QTc interval 
prolongation-related morbidity or mortality were observed. The proportion 
of patients with musculoskeletal AEs was comparable between treatment 
arms; no drug-related events were reported. Clinical cure rates were 84.6% 
and 95.5% in the MXF and COMP arms, respectively, in patients with con-
firmed pathogen(s) at baseline.
Conclusions: MXF treatment was well tolerated in children with cIAIs. 
However, a lower clinical cure rate was observed with MXF treatment com-
pared with COMP. This study does not support a recommendation of MXF 
for children with cIAIs when alternative more efficacious antibiotics with 
better safety profile are available.
Key Words: moxifloxacin, pediatric patients, complicated intra-abdominal 
infection, comparator, safety
(Pediatr Infect Dis J 2018;37:e207–e213)
Complicated intra-abdominal infections (cIAIs) represent a spectrum of conditions including peritonitis, intraperitoneal 
abscess and visceral abscess and are defined as infections that 
extend beyond the hollow viscus into a normally sterile area of the 
abdomen.1
Typically, patients with cIAIs present with clinical signs and 
symptoms of either peritonitis or abscess formation. Among the 
spectrum of intra-abdominal conditions that may lead to a cIAI in 
children, perforation of the appendix is the most common. Infec-
tions can also occur if the bowel wall integrity is compromised, for 
example, by ischemia or trauma.2,3
As for adults, general treatment principles for cIAIs in chil-
dren involve surgical or percutaneous radiologic intervention fol-
lowed by antimicrobial therapy4 and the recommended regimens, 
including aminoglycosides, carbapenems, β-lactam/β-lactamase 
inhibitor combination or advanced-generation cephalosporins.4
Moxifloxacin (MXF) is a fourth-generation fluoroquinolone 
antimicrobial with good in vitro activity against most causative 
organisms involved in cIAIs. MXF penetrates well into inflamed 
gastrointestinal tissues,5,6 and the benefits in adult cIAIs have been 
demonstrated in 4 double-blind, randomized, active-controlled 
clinical studies.7–10 Hence, it is a recommended treatment option 
for cIAIs in adults.4
The use of fluoroquinolones in children is limited to special 
indications, such as inhalation anthrax, and only when alternative 
antibiotics with a more favorable safety profile are not available.11 
These recommendations are regularly updated in the light of new 
information and address the safety concerns with these agents in 
pediatric patients. Thus, cardiac adverse events (AEs), tendon dis-
orders and polyneuropathy12,13 may be a particular concern in pedi-
atric patients.
The MOXIPEDIA (Moxifloxacin in Pediatric Subjects 
With Complicated Intra-abdominal Infection) study was designed 
to evaluate the safety of intravenous/oral MXF compared with 
sequential treatment with intravenous ertapenem followed by oral 
amoxicillin/clavulanate in children with cIAIs, focusing on muscu-
loskeletal AEs and cardiac AEs, and also on heart rate–corrected 
QT interval prolongation according to Bazett (QTcB) and Frideri-
cia (QTcF) formulae.
METHODS
Study Design and Population
The MOXIPEDIA study (NCT01069900) was a prospec-
tive, randomized, double-blind, double-dummy, active-controlled, 
parallel group, multicenter Phase 3 study in pediatric and adoles-
cent patients with cIAIs. The patient population was divided into 
4 age groups: adolescents (aged 12 to <18 years), school children 
(aged 6 to <12 years), preschool children (aged 2 to <6 years) and 
infants and toddlers (aged 3 months to <2 years).
Accepted for publication December 8, 2017.
From the *Department of Pediatrics, HELIOS Medical Center, Wuppertal, Ger-
many; †Department of Pediatric Surgery, The Montreal Children’s Hospital 
of the McGill University Health Centre, Montreal, Quebec, Canada; ‡Uni-
versity Children’s Hospital, Children’s Surgery Department, Riga, Latvia; 
§Regional Children Clinical Hospital, Dnepropetrovsk, Ukraine; ¶Bayer Inc, 
Mississauga, Ontario, Canada; ║Bayer, Whippany, New Jersey; **Bayer AG, 
Wuppertal, Germany; and ††Bayer AG, Berlin, Germany.
Presented in part at the Interscience Conference of Antimicrobial Agents and 
Chemotherapy (ICAAC)/International Congress of Chemotherapy and 
Infection (ICC) 2015; September 17−21, 2015; San Diego. Abstract G-1203.
The hospitals where Prof Stefan Wirth, Prof Sherif Emil, Prof Arnis Engelis and 
Prof Valeri Digtyar, respectively, are consultant physicians received payment 
for contribution in the clinical study. Dr Margarita Criollo, Carl DiCasoli, Dr 
Heino Stass, Dr Stefan Willmann, Dr Richard Nkulikiyinka and Dr Ulrike 
Grossmann are employees of Bayer AG. This study was sponsored and 
funded by Bayer AG, Leverkusen, Germany.
Address for correspondence: Ulrike Grossmann, MD, Bayer AG, 13353 Berlin, 
Germany. E-mail: ulrike.grossmann@bayer.com.
Supplemental digital content is available for this article. Direct URL citations 
appear in the printed text and are provided in the HTML and PDF versions of 
this article on the journal’s website (www.pidj.com).
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Antimicrobial reports
ISSN: 0891-3668/18/3708-e207
DOI: 10.1097/INF.0000000000001910
Moxifloxacin in Pediatric Patients With  
Complicated Intra-abdominal Infections
Results of the MOXIPEDIA Randomized Controlled Study
Stefan Wirth, MD,* Sherif G. S. Emil, MD, CM,† Arnis Engelis, MD,‡ Valeri Digtyar, MD,§  
Margarita Criollo, MD,¶ Carl DiCasoli, PhD,║ Heino Stass, PhD,** Stefan Willmann, PhD,**  
Richard Nkulikiyinka, MD,†† and Ulrike Grossmann, MD,†† on behalf of the MOXIPEDIA Study Group
The Pediatric Infectious Disease Journal
37
8
0891-3668
PIDJ
PIDJ-217-517
Safety of Moxifloxacin in Children
Wirth et al
2018
August
e207
e213
10.1097/INF.0000000000001910
2018
Pediatr Infect Dis J
Lippincott Williams & Wilkins
Hagerstown, MD
Remya Reghu
XXX
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Wirth et al The Pediatric Infectious Disease Journal • Volume 37, Number 8, August 2018
e208 | www.pidj.com © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Patients with the diagnosis of cIAI including a single or mul-
tiple intra-abdominal abscess or macroscopic intestinal perforation 
with localized or diffuse peritonitis either surgically confirmed or 
supported with radiologic evidence were eligible. All patients had 
undergone an initial surgical or interventional radiology procedure 
with or without postoperative drainage of abdominal cavity at base-
line. The main exclusion criteria are shown in Supplemental Digital 
Content 1, http://links.lww.com/INF/C949.
The study was conducted in agreement with the Declara-
tion of Helsinki, current amendment, the guideline for Good 
Clinical Practice and local regulatory requirements. The protocol 
was approved by the ethics committee at each participating site. 
Informed consent was obtained from patients’ parents or guardians 
before enrollment into the study.
Study Medications
Eligible patients were assigned in a 2:1 ratio to receive either 
intravenous/oral MXF or intravenous ertapenem followed by oral 
amoxicillin/clavulanate suspension (COMP) (Table 1), commenc-
ing immediately before or after surgery and interventional radiol-
ogy. The total treatment duration was 5 to 14 days at the discretion 
of the investigator, with a minimum duration of 3-day intravenous 
administration.
The MXF dosing regimens (Table 1) were based on a com-
plementary Phase 1 study (NCT01049022)14,15 and physiologically 
based pharmacokinetic modeling (data not shown) to ensure an 
adequate dosing of MXF, equivalent to the recommended 400 mg 
dose for adults. Age- and body weight–scaled intravenous infusions 
of MXF were administered over a period of 60 minutes, and oral 
MXF doses were provided as 50 or 400 mg tablets. Ertapenem and 
amoxicillin/clavulanate doses were based on their respective labels 
(Table 1).
Primary and Secondary Endpoints
The primary objective was safety in the overall pediatric 
population during the entire study period and during the follow-up 
period, with endpoints of overall AEs and cardiac and musculoskel-
etal AEs. Secondary endpoints included clinical and bacteriologic 
responses determined at test of cure (TOC) (Supplemental Digital 
Content 1, http://links.lww.com/INF/C949).
Safety Assessments
Safety data were collected at regular visits comprising pre-
treatment (baseline), treatment Day 1, during therapy (treatment 
Days 3–5), on the day of switch from intravenous to oral therapy if 
applicable, at end of treatment (EOT, last administration of MXF 
or COMP) and TOC (28 to 42 days after EOT). Assessments com-
prised AEs (according to the Medical Dictionary for Regulatory 
Activities [MedDRA], version 17.1); vital signs (maximum body 
temperature, heart rate, respiratory rate, systolic and diastolic blood 
pressure); a complete physical examination including abdomen and 
evaluation of surgical wound (except at pretreatment); laboratory 
assessments (blood chemistry, hematology, coagulation, urine anal-
ysis) and concomitant prescribed medication. In female patients 
of childbearing potential, a pregnancy test was performed before 
administration of any study medication and at EOT.
Standard 12-lead electrocardiogram (ECG) was recorded 
in each patient using Mortara ELI 250 ECG machines (Mortara 
Instrument Inc., Milwaukee, WI) before and after cessation of 
MXF or COMP infusion on treatment Days 1 and 3. The digital 
ECG recordings were transmitted electronically to a specified ECG 
core laboratory (Quintiles, United Kingdom) for semiautomated 
and manually verified analyses of ECG parameters (RR, PR, QRS 
and QT intervals). All ECG parameters were verified by a physi-
cian with pediatric cardiology expertise. QT intervals were given as 
heart rate–uncorrected QT, as well as QTcB and QTcF.
A standardized thorough musculoskeletal assessment exam-
ining shoulder, elbow, wrist, hip, knee, ankle, Achilles tendon and 
patellar tendon at both sides regarding swelling, pain, tenderness, 
warmth or any loss of normal function was performed at regular 
visits and additionally at 3 months and 1 year after EOT. Parents 
also completed a musculoskeletal questionnaire relating to exist-
ence in medical history of psoriasis, chronic inflammatory bowel 
disease (eg, Crohn’s disease or ulcerative colitis), bone and/or carti-
lage defects, congenital diseases (eg, cerebral palsy), cystic fibrosis 
and current limitations in age-appropriate physical activity behav-
iors of the child. All patients who had musculoskeletal AEs 1 year 
after EOT were to be followed-up until resolution or yearly for up 
to 5 years, if resolution did not occur before.
Statistical Methods
Sample Size
The study was designed as safety trial, with planned enroll-
ment of approximately 300 MXF-treated patients and 150 COMP-
treated patients. With this number of MXF-treated patients, if a 
specific AE is not seen, its event rate can be assumed with 95% 
confidence to be <1%.
Statistical Analysis
All statistical analyses were performed using SAS 9.1 (SAS 
Institute Inc., Cary, NC). The analysis of safety and efficacy data 
was descriptive, and no formal statistical testing was performed. 
The main analysis was performed on the safety population, com-
prising all randomized patients receiving at least one dose of study 
medication. Efficacy data were also analyzed for the modified 
intent-to-treat population, defined as all patients valid for safety 
TABLE 1. Dosing Regimens for MXF and COMP
Age and BW Category Intravenous Oral
MXF
  3 months to  
<2 years
6 mg/kg BW bid* No switch to oral
  ≥2 to <6 years
   BW <20 kg 5 mg/kg BW bid* No switch to oral
   BW ≥20 kg 5 mg/kg BW bid* 5 mg/kg BW bid*†
  ≥6 to <12 years
   BW <20 kg 4 mg/kg BW bid* No switch to oral
   BW ≥20 kg 4 mg/kg BW bid* 4 mg/kg BW bid*†
  ≥12 to <18 years
   BW <45 kg 4 mg/kg BW bid* 4 mg/kg BW bid*†
   BW ≥45 kg 400 mg od 400 mg od‡
COMP
 Ertapenem Amoxicillin/Clavulanate
  3 months to  
<2 years
15 mg/kg BW bid§ No switch to oral
  ≥2 to <6 years
   BW <20 kg 15 mg/kg BW bid§ No switch to oral
   BW ≥20 kg 15 mg/kg BW bid§ 22.5/3.2 mg/kg BW bid¶
  ≥6 to <12 years
   BW <20 kg 15 mg/kg BW bid§ No switch to oral
   BW ≥20 kg 15 mg/kg BW bid§ 22.5/3.2 mg/kg BW bid¶
  ≥12 to <18 years
   12 years 15 mg/kg BW bid§ 22.5/3.2 mg/kg BW bid¶
   ≥13 to <18 years 1 g od 22.5/3.2 mg/kg BW bid¶
*Not exceeding 400 mg daily.
†Provided in 50 mg tablets.
‡Provided as a 400 mg tablet.
§Not exceeding 1 g daily.
¶Not exceeding 875 mg amoxicillin/125 mg clavulanate bid.
bid indicates twice daily; BW, body weight; od, once daily.
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who had at least one pretreatment causative organism from the pri-
mary site of infection or from blood cultures. Results are expressed 
as frequency counts and percentages unless otherwise stated. In 
addition, within-treatment group 95% confidence intervals (CIs) 
are provided for the safety parameters.
RESULTS
Patient Disposition
Of 478 children screened between January 2010 and 2015, 
458 were eligible for inclusion and were randomized (Fig. 1). Seven 
children (MXF: n = 4 and COMP: n = 3) discontinued after randomi-
zation but before taking any study medication. Altogether, 301/305 
patients in the MXF arm and 150/153 patients in the COMP arm 
were treated. Thirty patients (MXF: n = 26 and COMP: n = 4) did not 
complete study medication; the most common reasons were occur-
rence of an AE (n = 17) and withdrawal of parental consent (n = 4).
Patient Demographics and Baseline Characteristics
The median (range) overall age of the population was 13 
years (3 months to 17 years), the majority (>90%) being 6 to 17 
years of age; only 22 patients <6 years of age were treated (Table 2). 
Clinically, most children presented with abdominal pain, rigidity 
of abdominal wall and abdominal tenderness. The most frequent 
diagnoses were localized or diffuse peritonitis. Most patients (95%) 
had undergone an appendectomy. None of the patients in the MXF 
arm and 2 patients in the COMP arm received any antibiotic (ie, 
cefoxitin plus levofloxacin plus metronidazole and ciprofloxacin, 
respectively) before surgery or interventional radiology.
The mean (range) duration of treatment was 8.7 (1–24) days 
for MXF and 8.7 (1–14) days for COMP. The mean (range) dura-
tion of intravenous treatment was 6.2 (1–15) days for MXF and 6.3 
(1–14) days for COMP, and oral treatment was 4.4 (1–12) days for 
MXF and 4.3 (1–11) days for COMP, respectively. Seven children 
received MXF for >14 days (up to 24 days).
Safety
The overall incidence rate of any AE was similar between 
the treatment arms: 175/301 patients (58.1%; 95% CI: 52.6–63.7%) 
for MXF and 82/150 patients (54.7%; 95% CI: 46.7–62.6%) for 
COMP (Table 3). The majority of AEs were mild or moderate. The 
incidence rate of severe AEs was 12/301 (4.0%) for MXF and 3/150 
(2.0%) for COMP. Drug-related AEs occurred in 14.3% (43/301) of 
MXF-treated patients (95% CI: 10.3–18.2%) and 6.7% (10/150) of 
COMP patients (95% CI: 2.7–10.7%). The incidence rate of serious 
AEs was similar between the 2 treatment arms, and no drug-related 
serious AEs occurred. All but one AE (one patient had newly diag-
nosed Crohn’s disease receiving MXF) recovered/resolved by the 
end of the study. No death was reported in the study. More patients 
in the MXF arm discontinued the treatment because of an AE com-
pared with those in the COMP arm (Table 3).
The most common AEs by MedDRA Preferred Term were 
ECG QT prolonged, incision site pain, vomiting and wound infec-
tion (Table 4). No relevant differences in incidence rates of the most 
common AEs were observed between the 2 treatment arms, except for 
ECG QT prolongation (28/301 [9.3%] of MXF-treated patients versus 
4/150 [2.7%] of COMP-treated patients). The incidence of the most 
commonly reported AEs was not higher in the younger age groups.
Electrocardiographic QT/QTc Changes
The incidence of drug-related QT prolongation in ECG 
recordings was 7.0% in the MXF arm (95% CI: 4.4–10.3; one event 
being assessed by the investigator as a severe AE) and 1.3% in the 
COMP arm (95% CI: 0.2–4.7).
No cases of QTc interval prolongation–related morbidity or 
mortality (ie, clinical cardiac signs and symptoms) were observed.
Screening failed
N = 20
Moxifloxacin
N = 305
Comparator
N = 153
4 patients did not receive study 
drug:
Protocol violation: 3 
Consent withdrawn: 1
150 patients treated and 
eligible for safety 
analysis
301 patients treated and 
eligible for safety 
analysis
3 patients did not receive 
study drug:
Protocol violation: 1
Technical problem: 1 
Pre-dose AE: 1
26 patients did not 
complete treatment:
AE: 15
Consent withdrawn: 4
Protocol violation: 2
Other: 5
275 patients completed 
treatment
4 patients did not 
complete treatment:
AE: 2
Consent withdrawn: 0
Protocol violation: 0
Other: 2
146 patients completed 
treatment
Screened patients
N = 478
Randomized patients
N = 458
246 patients had 
confirmed pathogen
(mITT population)
133 patients had 
confirmed pathogen
(mITT population)
FIGURE 1. Patient disposition. mITT indicates modified intent-to-treat.
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Ten patients (3.3%) discontinued MXF early because of 
uncorrected QT interval prolongation. A case of QTcB (+24 ms) 
and QTcF (+13 ms) prolongation after 400 mg MXF infusion at 
Day 1 resolved on the same day after MXF withdrawal.
Musculoskeletal Adverse Events
A comparable proportion of patients in the MXF and 
COMP arms experienced a musculoskeletal AE [13/301 patients 
(4.3%; 95% CI: 2.3–7.3) and 5/150 patients (3.3%; 95% CI: 
1.1–7.6), respectively]. No musculoskeletal events were assessed 
by the investigators as being related to either study medication 
(Table 5).
Most events were mild and started from 3 weeks to 1 year 
after start of study medication. There was one serious musculoskel-
etal AE, a forearm fracture in an 11-year-old male patient occurring 
about 7 months after EOT with MXF. All events recovered/resolved 
at the end of the study.
Efficacy
In the modified intent-to-treat population, bacteriologic 
 success and clinical cure at TOC were achieved in 208/246 (84.6%) 
MXF-treated patients and 127/133 (95.5%) COMP-treated patients 
(Fig., Supplemental Digital Content 1, http://links.lww.com/INF/
C949). Similar results were found in the safety population. Clini-
cal success rates were similar across all age groups. One of the 
COMP-treated patients who received antibiotics before surgery or 
interventional radiology (cefoxitin plus levofloxacin plus metroni-
dazole) was assessed as clinical and bacteriologic success at TOC, 
whereas the other patient who received preoperatively ciprofloxa-
cin was graded as failure because of occurrence of a mechanical 
ileus 17 days after the end of COMP treatment.
Clinical failure was reported in 38/246 [15.4%; of which 
21/246 (8.5%) had indeterminate clinical response] MXF-treated 
patients and 6/133 [4.5%; of which 3/133 (2.3%) had indetermi-
nate response] COMP-treated patients. Among patients treated 
with MXF, 8.1% (20/246 patients) had either relapse of cIAI, or 
abscess formation or retention of purulent exudate in abdominal 
cavity, or presumed persistence of causative pathogen was observed 
or administration of other antimicrobial agents additional to study 
medication or after EOT, while 1.5% (2/133 patients) among 
COMP-treated patients had an infectious failure (Table 6).
Further details on efficacy are given in Supplemental Digital 
Content 1, http://links.lww.com/INF/C949.
DISCUSSION
In this study, the safety and efficacy of intravenous/oral 
MXF was compared with that of intravenous ertapenem followed 
by oral amoxicillin/clavulanate in pediatric patients (3 months to 
17 years) with cIAIs. Both treatment regimens were well tolerated 
by patients regardless of their age, although there were more drug-
related AEs with MXF compared with COMP. In both treatment 
arms, a similar proportion of patients experienced musculoskeletal 
AEs. Clinical success rates at TOC were lower with MXF compared 
with COMP.
Approximately 90% of cIAIs in children are because of per-
forated appendicitis.16–19 In this study, 95% of the patients in each 
treatment arm across all age groups underwent an appendectomy, 
indicating a high incidence of appendicitis. The most frequent diag-
noses were localized peritonitis (limited to one quadrant) in older 
children (aged 12 to <18 years) and diffuse peritonitis (2 or more 
quadrants) in children below 12 years of age, the latter being con-
sistent with the inability of the underdeveloped omentum to limit 
purulent effusion from a perforation.20
In the present study, clinical cure and bacteriologic 
 success rates with MXF were comparable to those previously 
reported in adults with cIAIs.7,10,21 Considering that MXF shows a 
TABLE 2. Patient Demographics and Baseline 
Characteristics (Safety Population)
Variable
MXF  
(N = 301)
COMP  
(N = 150)
Total  
(N = 451)
Age (years)
  Mean 12.03 12.05 12.04
  SD 3.68 3.48 3.61
  Median 13 13 13
  Range 0.25–17 3–17 0.25–17
Age group (years), N (%)
  0.25–<2 1 (0.3) 0 1 (0.2)
  2–<6 14 (4.7) 7 (4.7) 21 (4.7)
  6–<12 100 (33.2) 51 (34.0) 151 (33.5)
  12–<18 186 (61.8) 92 (61.3) 278 (61.6)
Gender, N (%)
  Male 179 (59.5) 98 (63.5) 277 (61.4)
  Female 122 (40.5) 52 (34.7) 174 (38.6)
Race, N (%)
  White 289 (96.0) 142 (94.7) 431 (95.6)
  Black 1 (0.3) 1 (0.7) 2 (0.4)
  Hispanic 8 (2.7) 6 (4.0) 14 (3.1)
  Native Hawaiian or  
other pacific islander
1 (0.3) 0 1 (0.2)
  Uncodable 2 (0.7) 1 (0.7) 3 (0.7)
Body temperature (°C)
  Mean 37.67 37.59 37.64
  SD 0.76 0.71 0.75
  Median 37.7 37.6 37.7
  Range 35.20–40.70 35.30–39.00 35.20–40.70
Abdominal pain, n (%)
  Mild 45 (15.0) 17 (11.3) 62 (13.7)
  Moderate 116 (38.5) 60 (40.0) 176 (39.0)
  Severe 91 (30.2) 47 (31.3) 138 (30.6)
  None 49 (16.3) 26 (17.3) 75 (16.6)
Abdominal tenderness  
with rebound, N (%)
  Present 185 (61.5) 93 (62.0) 278 (61.6)
  Absent 116 (38.5) 57 (38.0) 173 (38.4)
Primary diagnosis, N (%)
  Single intra-abdominal  
abscess
50 (16.6) 23 (15.3) 73 (16.2)
  Multiple intra- 
abdominal abscesses
2 (0.7) 0 2 (0.4)
  Localized peritonitis  
(limited to one quad-
rant)
148 (49.2) 74 (49.3) 222 (49.2)
  Diffuse peritonitis  
(2 or more quadrants)
101 (33.6) 53 (35.3) 154 (34.1)
SD indicates standard deviation.
TABLE 3. Summary of Adverse Events (Safety 
Population)
AEs
MXF  
(N = 301),  
N (%)
COMP  
(N = 150),  
N (%)
Any AE 175 (58.1) 82 (54.7)
Any drug-related AE 43 (14.3) 10 (6.7)
Any serious AE 20 (6.6) 6 (4.0)
Any drug-related serious AE 0 0
Discontinuation of study  
medication because of AE
16 (5.3) 2 (1.3)
Discontinuation of study medication 
because of serious AE
1 (0.3) 0 (0)
Death 0 (0) 0 (0)
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concentration-dependent bactericidal activity driven by the maxi-
mum drug concentration in plasma and the area under the plasma 
concentration–time curve, effective dosing regimens are needed for 
pediatric patients to achieve comparable systemic drug exposures as 
in adults treated with 400 mg MXF once daily.5,6 This was attained 
by the age- and body weight–dependent dosing scheme of MXF, 
which was developed using physiologically based pharmacokinetic 
modeling on the basis of MXF exposure parameters that are con-
sidered safe and efficacious in adults.14,15 Achievement of adequate 
systemic MXF exposure in pediatric patients was confirmed by 
a subsequent retrospective population pharmacokinetic analysis 
(data not shown).
The efficacy of MXF was numerically lower than that of 
COMP. No historical data exists on the efficacy of intravenous 
ertapenem followed by oral amoxicillin/clavulanate in children with 
cIAIs. In studies with ertapenem in adults, clinical success rates 
were between 79% and 93% for a 14-day regimen for cIAIs10,22–26 
and 97% for a 3-day regimen for localized peritonitis.27 In children 
with cIAIs, clinical success rates of 82%–94% have been described 
for ertapenem.19,28 Interestingly, in the present study, the clinical 
cure rate with MXF treatment tended to be higher in Europe than 
in North America (87.8% vs. 70.8% at the TOC visit). However, 
the overall number of patients treated with study medication in the 
North America region was low.
Differences in physiology and pharmacokinetics between 
children and adults can profoundly affect the safety and efficacy 
of antibiotics in children.29 In particular, potential fluoroquinolone-
related musculoskeletal toxicity is a serious safety concern. While 
this has been observed in animal studies, with damage to articular 
cartilage in weight-bearing joints in juvenile animals,30–32 there is no 
comparable documentation of fluoroquinolone-induced arthropathy 
in humans. Overall, fluoroquinolone-associated musculoskeletal tox-
icity is relatively infrequent and transient in clinical studies.33 In our 
study, no relevant difference between treatment arms in the propor-
tion of patients experiencing musculoskeletal events was observed.
TABLE 4. Incidence of Adverse Events by MedDRA Preferred Term 
Occurring in ≥2% Patients in Either Treatment Arm Irrespective of 
Relation to Study Medication (Safety Population)
MedDRA Preferred Term
MXF (N = 301), N (%) COMP (N = 150), N (%)
Any AE Drug-related Any AE Drug-related
Abdominal pain 8 (2.7) 0 3 (2.0) 0
Diarrhea 11 (3.7) 6 (2.0) 1 (0.7) 0
Vomiting 20 (6.6) 1 (0.3) 12 (8.0) 2 (1.3)
Procedural vomiting 0 0 4 (2.7) 0
Pyrexia 6 (2.0) 0 4 (2.7) 0
Wound infection 14 (4.7) 0 6 (4.0) 0
Incision site pain 26 (8.6) 0 14 (9.3) 0
Procedural pain 16 (5.3) 0 10 (6.7) 1 (0.7)
Incision site inflammation 2 (0.7) 0 3 (2.0) 1 (0.7)
AST increased 2 (0.7) 0 3 (2.0) 2 (1.3)
ECG QT prolonged 28 (9.3) 21 (7.0) 4 (2.7) 2 (1.3)
Headache 6 (2.0) 0 2 (1.3) 0
Phlebitis 8 (2.7) 0 0 0
AST indicates aspartate aminotransferase.
TABLE 5. Incidence of Musculoskeletal Adverse Events (Safety 
Population)
MedDRA Preferred Term
MXF (N = 301), N (%) COMP (N = 150), N (%)
Any AE Drug-related Any AE Drug-related
Forearm fracture 1 (0.3) 0 0 0
Joint injury 0 0 1 (0.7) 0
Ligament sprain 1 (0.3) 0 1 (0.7) 0
Muscle strain 0 0 1 (0.7) 0
Arthralgia 9 (3.0) 0 1 (1.3) 0
Joint swelling 0 0 1 (0.7) 0
Musculoskeletal pain 3 (1.0) 0 0 0
Myalgia 1 (0.3) 0 0 0
TABLE 6. Overview of Causes of Clinical Failure at 
Test of Cure (mITT Population)
Clinical Response
MXF (n = 246),  
N (%)
COMP (n = 133),  
N (%)
Any clinical failure 38 (15.4) 6 (4.5)
Infectious failure* 20 (8.1) 2 (1.5)
Reoperation 1 (0.4) 1 (0.7)
Wound infection 7 (2.8) 1 (0.7)
Early withdrawal from  
study because of AE†
9 (3.7) 2 (1.5)
Other‡ 1 (0.4) 0
Death 0 0
*Includes relapse of cIAI, abscess formation, retention of purulent exudate in 
abdominal cavity, administration of other antimicrobial agents additional to study 
medication or after EOT or presumed persistence of causative pathogen.
†Includes prolongation of QT interval (7 MXF-treated patients and 1 COMP-
treated patient) and administration of other antimicrobial agents because of AE 
(2 MXF-treated patients presenting endocarditis or mechanical ileus and 1 COMP-
treated patient presenting mechanical ileus).
‡Includes unavailability of study medication at investigational site.
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In general, the safety and tolerability of MXF in children 
was comparable to that in adults, and no unexpected adverse drug 
reactions were observed. As expected, MXF induced a small ECG 
QTc prolongation. The mean QTc interval with intravenous MXF 
was within the range of that reported in adults receiving MXF 
400 mg,13 despite higher heart rate values in pediatric patients. 
Prolongation of the QTc interval increases the risk of Torsade 
de Pointes (TdP) arrhythmia, which might be a fatal arrhythmia, 
especially when the QTc interval exceeds 500 ms or the prolonga-
tion is greater than 60 ms compared with the pretreatment value. 
Currently, information on the potentially low risk of MXF-asso-
ciated TdP or other ventricular arrhythmias are based only on 
data in adult patients, and no information is available for pediatric 
patients.34 Furthermore, it is unknown if any predisposing factors 
identified in adults (excluding older age) such as female sex, brad-
ycardia, hypokalemia, hypocalcemia, hypomagnesemia, history of 
cardiac disease and treatment with more than one QTc-prolonging 
medication13 also apply to pediatric subjects. Subjects with some 
of these risk factors were excluded from the current study; there-
fore, any link between MXF-induced QTc prolongation and risk 
factors could not be established. Our data did not indicate a higher 
propensity for MXF-induced QTc prolongation in children com-
pared with adults.
This study had some limitations, including that the sample 
size was not calculated for primary analysis of efficacy, and no non-
inferiority margin for the treatment effect of MXF compared with 
COMP was considered, thus, limiting the ability to make conclu-
sive inferences on efficacy. Also, the variety of cIAI diagnoses was 
limited. The time point for primary assessment of clinical success 
differs from that of the current FDA guidance35 because the study 
was designed before its availability.
In summary, the sequential administration of MXF treat-
ment was well tolerated in children with cIAIs. The general safety 
profile and efficacy of MXF was consistent with that in adult 
patients. However, MXF monotherapy appeared less efficacious 
than ertapenem followed by amoxicillin/clavulanate, an antimicro-
bial treatment regimen recommended by evidence-based guidelines 
for children. These results do not support MXF to be recommended 
for pediatric patients with cIAIs when alternative efficacious anti-
biotics with better safety profile are available.
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